Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
about
Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndromeA clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersMyelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and managementBeyond hypomethylating agents failure in patients with myelodysplastic syndromesNew ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromeInfections in myelodysplastic syndromesThe DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2'-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer CellsOral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid LeukemiaManagement of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Established and emerging targeted therapies in the myelodysplastic syndromes.Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study.Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.Epigenetic therapies in MDS and AMLCurrent therapy of myelodysplastic syndromesAzacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.Clinical development of demethylating agents in hematologyDevelopment of an oral form of azacytidine: 2'3'5'triacetyl-5-azacytidine.Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.Epigenetics and the overhealing wound: the role of DNA methylation in fibrosis.The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients.Digging deep into "dirty" drugs - modulation of the methylation machinery.Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome.Azacitidine in the management of patients with myelodysplastic syndromes.Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.Chronic myelomonocytic leukemia: Forefront of the field in 2015.Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia.The future of epigenetic therapy in solid tumours--lessons from the past.Epigenetic regulation of the human telomerase reverse transciptase gene: A potential therapeutic target for the treatment of leukemia (Review).Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model.Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.Molecular therapeutic approaches for pediatric acute myeloid leukemia.Promises and challenges of anticancer drugs that target the epigenome.Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management.
P2860
Q24632949-EF8FA5C8-E604-436D-B5CA-C4AAE4890CBFQ26743743-428926F7-4B4D-48E5-8C29-AB20D4BCAA1CQ26796240-9A395C96-728F-4596-A52D-71DE78CD6620Q26827079-48754555-18FC-42FE-A5B6-C86E0F8D47E7Q26829132-E0B54C0B-7D59-49FF-82E8-D0488F097B2DQ26859275-F5F435C4-D9CF-4BD7-B375-DD1EC39763F2Q27313466-B0D7D790-9037-49B5-94F6-25CAF389B4FFQ28084813-390F9A40-5170-4876-996B-E7F4747BEE0FQ30235355-4054D5CA-A456-4DBB-AAEC-3303DCC47442Q30245476-67929F5C-49FC-487D-B359-088B5C3A6919Q33404975-41750766-0495-443F-9D4F-C784BA0F2253Q33405470-EEB85BFC-9F4E-4971-B9B7-CE9BF3F5949AQ33408184-3BB6D901-C05C-498B-8E8B-15C0B5EED50AQ33410375-A8B98523-A12D-497D-9FB2-796D743686C6Q33429873-584A2175-4192-448F-B6CE-B2D8F34FBA9DQ33600822-273A4D89-61AC-4965-8D1C-8F4BA31A3D86Q33863567-DF5B2C16-0461-4911-8BE7-5BD3BC9CD87BQ34013796-ACCC13D3-FE7D-40D0-BD20-B6B053CA93F6Q34273735-DC911933-8EC3-4226-8A19-5FF55627A449Q34350209-D2301514-ECA7-45E7-978E-083EB90CF81DQ34395179-27A8E119-BAA2-4EF7-9EB6-FE70CA8C41C0Q35687461-1B593453-1624-44AE-AE86-BC8953DABF16Q35752467-9332F97D-F8AB-4050-9276-917FADE4D53AQ35964716-A8D83534-0942-400D-B0F5-006312B1AC95Q36113039-A533E216-BDFC-4AAB-9F4E-9E00233B6336Q36138278-01A254B5-CC49-4A5F-A432-1419557063F2Q36523796-18731826-C2FD-4451-9D56-0A77814BD2A0Q36544042-2850D365-CE7F-4243-9B80-783039C0EAC6Q36768610-8D85430F-B6EC-46AC-B090-7F3BFAA7AB4CQ36799188-9C320FBE-A81B-488E-9BC7-ABC8B73AE811Q36876853-2BD4B499-39B3-4DD2-9EC1-C8A950FE9059Q36967029-153F925A-F6EF-4A3A-B832-BE0C40E2332FQ37061554-3FA09C3C-B1D0-4ED1-A222-50D541C05139Q37211663-2D602289-63D2-4241-83F5-14826C3283B3Q37214386-ED3D4B0F-928A-4C92-A3C7-2BF73415DD10Q37349392-34ACEF5B-FFB1-4E4C-B1BB-FE4C6FD01D6AQ37643136-0234E47C-CECF-47E9-822D-40C9A3BC8D2FQ37962596-EDC57963-D09D-4E43-876B-BEE33E35AF18Q38012085-0BFC4923-B93D-4098-8735-10BECD2A7580Q38018571-38D9A5A5-2E90-447C-84CB-C7A6429BA6C1
P2860
Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Phase I study of oral azacitid ...... a, and acute myeloid leukemia.
@en
type
label
Phase I study of oral azacitid ...... a, and acute myeloid leukemia.
@en
prefLabel
Phase I study of oral azacitid ...... a, and acute myeloid leukemia.
@en
P2093
P2860
P50
P356
P1476
Phase I study of oral azacitid ...... a, and acute myeloid leukemia.
@en
P2093
Barry Skikne
Christopher Cogle
Eric Laille
Heidi Giordano
Kyle J Macbeth
Renee Ward
Sarah Sakoian
Steven D Gore
P2860
P304
P356
10.1200/JCO.2010.34.4226
P407
P577
2011-05-16T00:00:00Z